Andrew Warwick Hamer Acquires 18,900 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock

Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Andrew Warwick Hamer purchased 18,900 shares of the business’s stock in a transaction dated Thursday, December 19th. The shares were acquired at an average price of C$1.88 per share, for a total transaction of C$35,606.69.

Cardiol Therapeutics Trading Up 0.6 %

Cardiol Therapeutics stock opened at C$1.81 on Thursday. Cardiol Therapeutics Inc. has a one year low of C$1.09 and a one year high of C$4.26. The company’s fifty day moving average price is C$2.32 and its two-hundred day moving average price is C$2.65. The company has a debt-to-equity ratio of 1.07, a current ratio of 2.39 and a quick ratio of 6.84. The company has a market capitalization of C$126.48 million, a price-to-earnings ratio of -4.11 and a beta of 0.70.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.